Literature DB >> 15262712

Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States.

Jennifer T Trent, Robert S Kirsner, Paolo Romanelli, Francisco A Kerdel.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15262712     DOI： 10.1001/archderm.140.7.890

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  8 in total

1.  Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.

Authors:  Megan H Noe; Misha Rosenbach; Rebecca A Hubbard; Arash Mostaghimi; Adela R Cardones; Jennifer K Chen; Jonathan Cotliar; Mark D P Davis; Arturo Dominguez; Lindy P Fox; Lauren C Hughey; Benjamin H Kaffenberger; Daniela Kroshinsky; Bernice Y Kwong; Daniel D Miller; Amy Musiek; Alex G Ortega-Loayza; Victoria R Sharon; Kanade Shinkai; Erika M Summers; Karolyn A Wanat; David A Wetter; Scott Worswick; David J Margolis; Joel M Gelfand; Robert G Micheletti
Journal:  JAMA Dermatol       Date:  2019-04-01       Impact factor: 10.282

2.  Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study.

Authors:  Samina Farhat; Muddasir Banday; Iffat Hassan
Journal:  J Clin Diagn Res       Date:  2016-01-01

Review 3.  Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date.

Authors:  Ousmane Faye; Jean-Claude Roujeau
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Diseases mimicking a burn - outcome and treatment.

Authors:  O Castana; M Makrodimou; D Michelakis; Z Tsandoulas; D Alexakis
Journal:  Ann Burns Fire Disasters       Date:  2005-09-30

5.  Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine.

Authors:  Hye Jung Park; Sung Ryeol Kim; Dong Woo Leem; Il Joo Moon; Beom Seok Koh; Kyung Hee Park; Jung-Won Park; Jae-Hyun Lee
Journal:  Eur J Clin Pharmacol       Date:  2014-10-21       Impact factor: 2.953

6.  Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.

Authors:  Carlos Gustavo Wambier; Thaís Angélica Hoekstra; Sarah Perillo de Farias Wambier; Roberto Bueno Filho; Fernando Crivelenti Vilar; Renato Soriani Paschoal; Ana Maria Roselino; Marco Andrey Cipriani Frade; Norma Tiraboschi Foss
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

7.  Are Multimorbidities Underestimated in Scoring Systems of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Like in SCORTEN?

Authors:  Tobias von Wild; Peter L Stollwerck; Thomas Namdar; Felix H Stang; Peter Mailänder; Frank Siemers
Journal:  Eplasty       Date:  2012-08-02

Review 8.  Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN).

Authors:  E C Kuijper; L E French; C P Tensen; M H Vermeer; J N Bouwes Bavinck
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05-15       Impact factor: 6.166
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.